AU2023271739A1 — Therapeutic compounds useful for the prophylactic or therapeutic treatment of an HIV virus infection
Assigned to Gilead Sciences Inc · Expires 2023-12-14 · 2y expired
What this patent protects
The present disclosure relates to a compound of formula (a), (b), (Ila), and (Ilb): F F F F F I~N I FF F F I N C1 0 ~ H ON N N-N O% F 0 (Ta) FF F O F F I~N NI N-N C % 5F O1:S- ..F F O (Tb) F F F F IN FH 0 H A N IN, L 0 (Ila) H:\Interwoven\NRPortb\DCC\V…
USPTO Abstract
The present disclosure relates to a compound of formula (a), (b), (Ila), and (Ilb): F F F F F I~N I FF F F I N C1 0 ~ H ON N N-N O% F 0 (Ta) FF F O F F I~N NI N-N C % 5F O1:S- ..F F O (Tb) F F F F IN FH 0 H A N IN, L 0 (Ila) H:\Interwoven\NRPortb\DCC\VZS\20024752_I.dex-3/26/2020 F F ". F F PN F N H F lyN CI F O O (IIb) which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.